
|Videos|August 11, 2022
Treatment of Patients Unfit for Intensive Induction with Venetoclax + Azacitidine
Author(s)Hetty E. Carraway, MD, Eytan Stein, MD
Hetty Carraway, MD, highlights the role of venetoclax + azacitidine in the treatment of patients with acute myeloid leukemia who are unfit for intensive induction therapy.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































